SGC, Department of Medicine,
Karolinska University Hospital and Karolinska Institutet,
171 65 Solna,
Michael Sundstrom received his PhD from Uppsala, followed by Postdoctoral studies at Karolinska Institute. From 1993-2000 he was at Pharmacia as Director for structure-based drug design and oncology R&D portfolio management. Between 2001 and 2003 he held senior positions at the Swedish Biotechs Actar and Biovitrum. In 2003 he joined the Structural Genomics Consortium (SGC) at the University of Oxford, as Chief Scientist. In 2007 he assumed the position as Managing Director for the Novo Nordisk Foundation Center for Protein Research (Copenhagen). In 2011, he was Vice President of Discovery Research at Karolinska Development. He then re-joined the SGC inmid-2014, as Scientific Director of European Initiatives at SGC.
Michael has three main responsibilities within the SGC; i) member of the global research leadership team coordinating projects and activities of common interest within the consortium; ii) site head for SGC Karolinska and iii) main scientific focus and responsibility for the SGC Tissue Platforms in Stockholm, Frankfurt, Toronto and Montreal; working to establish high quality cell-based assays using patient-derived cell systems in inflammation, oncology and neurodegenerative diseases.
Michael currently leads (ad interim) the efforts in the Tissue Assay platform at SGC Karolinska.
Nat. Chem. Biol.. 2015 11(8):536-41. doi: 10.1038/nchembio.1867
Nat Rev Drug Discov. 2015 14(3):149-50. doi: 10.1038/nrd4565
Curr Opin Pharmacol. 2014 17C:58-63. doi: 10.1016/j.coph.2014.07.015
Mol Cell.. 2013 51(6):707-22. doi: 10.1016/j.molcel.2013.08.002
Protein Sci.. 2011 20(3):597-609. doi: 10.1002/pro.593
Nat. Methods. 2008 5(10):854-5. doi: 10.1038/nmeth1008-854
Proc. Natl. Acad. Sci. U.S.A.. 2007 104(51):20523-8. doi: 10.1073/pnas.0708800104
Nature. 2007 448(7149):87-91. doi: 10.1038/nature05971
Drug Discov. Today. 2007 12(9-10):365-72. doi: 10.1016/j.drudis.2007.03.006